Table 4.
Vascular function in offspring of control and nutritionally restricted dams
| Day 20 | Day 100 | |||||
|---|---|---|---|---|---|---|
| C (n =7) | R (n = 6%) | C male (n = 6%) | R male (n = 5%) | C female (n = 5%) | R female (n = 6%) | |
| Lumen diameter (μm) | 277.8 ± 17.1 | 301.0 ± 40.8 | 302.3 ± 24.7 | 304.1 ± 27.8 | 369.6 ± 30.2 | 324.7 ± 29.6 |
| Maximal contraction | ||||||
| 125 mmol l−1 K (mN mm−1) | 2.26 ± 0.23 | 2.79 ± 0.46 | 1.96 ± 0.28 | 1.96 ± 0.53 | 2.81 ± 0.23 | 2.73 ± 0.31 |
| Phenylephrine (%K) | 45.7 ± 9.4 | 19.2 ± 7.7* | 71.6 ± 5.5 | 76.1 ± 2.8 | 76.8 ± 7.1 | 75.7 ± 2.3 |
| Noradrenaline (%K) | 31.1 ± 7.8 | 8.3 ± 3.7* | 98.3 ± 2.8 | 94.9 ± 5.0 | 98.0 ± 3.8 | 100.5 ± 3.1 |
| U46619 (%K) | 90.9 ± 9.0 | 97.6 ± 10.6 | 32.9 ± 4.6 | 55.2 ± 10.3* | 62.5 ± 8.7† | 49.9 ± 5.8 |
| Maximum relaxation | ||||||
| ACh (%) | 97.0 ± 1.3 | 90.4 ± 8.0 | 40.3 ± 4.1 | 51.7 ± 7.2 | 59.8 ± 9.1† | 69.4 ± 8.6 |
| SNP (%) | 98.2 ± 3.1 | 100.3 ± 3.4 | 96.5 ± 3.2 | 87.9 ± 3.8* | 98.2 ± 2.1 | 89.0 ± 2.4* |
| pEC50 (–log m) | ||||||
| K | — | — | — | — | — | — |
| Phenylephrine | 5.91 ± 0.23 | 5.75 ± 0.13 | 5.29 ± 0.11 | 5.17 ± 0.07 | 5.22 ± 0.08† | 5.32 ± 0.03 |
| Noradrenaline | — | — | 5.46 ± 0.17 | 5.24 ± 0.12 | 5.36 ± 0.12 | 5.42 ± 0.03 |
| U46619 | 6.82 ± 0.16 | 6.99 ± 0.30 | 6.27 ± 0.12† | 6.51 ± 0.11 | 6.47 ± 0.17 | 6.62 ± 0.14 |
| ACh | 7.19 ± 0.18 | 6.73 ± 0.07 | n.a. | n.a. | n.a. | n.a. |
| SNP | 7.64 ± 0.10 | 7.42 ± 0.19 | 7.40 ± 0.15 | 6.90 ± 0.24 | 7.15 ± 0.14 | 7.10 ± 0.21 |
| Day 200 | ||||
|---|---|---|---|---|
| C male (n = 6%) | R male (n = 6%) | C female (n = 5%) | R female (n = 5%) | |
| Lumen diameter (μm) | 245.4 ± 17.8 | 283.9 ± 13.9 | 282.7 ± 32.8 | 247.6 ± 23.8 |
| Maximal contraction | ||||
| 125 mmol l−1 K (mN mm−1) | 1.96 ± 0.26 | 2.52 ± 0.52 | 2.74 ± 0.50 | 1.89 ± 0.24 |
| Phenylephrine (%K) | 73.4 ± 4.3 | 75.9 ± 4.0 | 85.5 ± 3.8 | 79.0 ± 3.6 |
| Noradrenaline (%K) | 95.6 ± 3.9 | 88.9 ± 3.1 | 98.9 ± 3.0 | 96.7 ± 3.8 |
| U46619 (%K) | 22.1 ± 3.7 | 38.0 ± 3.7* | 44.6 ± 4.3†† | 50.9 ± 4.5 |
| Maximum relaxation | ||||
| ACh (%) | 30.4 ± 15.0 | 33.1 ± 8.2 | 21.9 ± 4.4 | 26.8 ± 3.5 |
| SNP (%) | 85.1 ± 4.3 | 85.8 ± 2.6 | 87.8 ± 2.1 | 88.2 ± 4.0 |
| pEC50 (–log m) | ||||
| K | 1.18 ± 0.01 | 1.30 ± 0.02** | 1.30 ± 0.01†† | 1.30 ± 0.03 |
| Phenylephrine | 5.27 ± 0.07 | 5.22 ± 0.06 | 5.37 ± 0.08 | 5.38 ± 0.12 |
| Noradrenaline | 5.40 ± 0.09 | 5.31 ± 0.11 | 5.53 ± 0.17 | 5.35 ± 0.05 |
| U46619 | 6.37 ± 0.05 | 6.75 ± 0.15* | 6.72 ± 0.12 | 6.59 ± 0.22 |
| ACh | n.a. | n.a. | n.a. | n.a. |
| SNP | 7.38 ± 0.09 | 6.94 ± 0.22 | 7.23 ± 0.13 | 6.98 ± 0.04 |
C. control; R, nutritional restriction. Values are given as means ± s.e.m.
†
P < 0.05
††
P < 0.01, male vs. female for same age and same group (R or C)
*
P < 0.05
**
P < 0.01, C vs. R of same sex at same age for responses observed to ACh at day 100 and day 200. % K, percentage of maximal contraction to 125 mmol l−1 KPSS. n.a., calculation of pEC50 was not appropriate.